PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3535201

[Osteodensitometry: a promising method for evaluating bone density in humans].

J Guimond·D Picard·R Chartrand·L Carrier·M Picard
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Bone Diseases, MetabolicBone and BonesHumansMineralsOsteoporosisRadionuclide ImagingJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Guimond, D Picard, R Chartrand, L Carrier, M Picard. 1986. [Osteodensitometry: a promising method for evaluating bone density in humans].. https://pubmed.ncbi.nlm.nih.gov/3535201/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Hyperimmunoglobulin E syndrome.

Hyperimmunoglobulin E (HIE) syndrome is a primary immunodeficiency disorder characterized by recurrent bacterial infections in presence of very high serum Ig E levels. We are reporting a nine-year-old child with HIE syndrome and reviewing literature on this disease.

Bone Diseases, Metabolic↗
PubMed2001

Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets.

Osteoprotegerin-ligand, also called Osteoclast Differentiation Factor or RANK-ligand, its receptor RANK and its decoy receptor Osteoprotegerin are key molecules regulating osteoclast differentiation and activation. In this view we discuss structure and expression of these molecules, the genetic models addressing their function and their role in in vivo models of osteoclast differentiation and activation. The new paradigm that has evolved from these studies, is not only important in normal bone homeostasis but also appears to play a role in different diseases that affect the skeleton, such as osteoporosis, inflammatory joint disease and cancer. It has opened a new era in bone research by increasing our molecular knowledge and providing new therapeutic targets in bone disease.

Bone Diseases, Metabolic↗
PubMed2001

Malignant hypophosphathaemic bone disease.

A case of crippling osteoporosis with muscular weakness, hypophosphatemia, hyperparathyroidism, defective skeletal calcification and cartilage destruction is reported. The patient, a male was observed from the age of 2 1/2 until his death at the age of 33 years. This bone/cartilage disease failed to respond to phosphate supplementation, parathyroidectomy and calcitriol. We believe this may represent a hitherto undescribed entity.

Bone Diseases, Metabolic↗